MA
KURA icon

MYDA Advisors’s Kura Oncology KURA Stock Holding History

MYDA Advisors’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-20,000
Closed -$412K – 175
2024
Q2 		$412K Sell
20,000
-6,000
-23% -$123K 0.09% 95
2024
Q1 		$555K Buy
26,000
+1,000
+4% +$19.4K 0.16% 82
2023
Q4 		$360K Sell
25,000
-55,000
-69% -$541K 0.12% 71
2023
Q3 		$730K Hold
80,000
– – 0.24% 62
2023
Q2 		$846K Buy
80,000
+60,000
+300% +$710K 0.25% 71
2023
Q1 		$245K Hold
20,000
– – 0.09% 95
2022
Q4 		$248K Hold
20,000
– – 0.15% 67
2022
Q3 		$273K Hold
20,000
– – 0.13% 109
2022
Q2 		$367K Hold
20,000
– – 0.1% 132
2022
Q1 		$322K Buy
+20,000
New +$289K 0.13% 136

Other funds holding KURA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MYDA Advisors's KURA Position: Q3 2024 in Review

MYDA Advisors sold out of Kura Oncology (KURA) in Q3 2024, closing a stake of 20,000 shares — an estimated $412K sold.

MYDA Advisors first reported a position in KURA in Q1 2022 and held it in 10 quarters. The position peaked at $846K in Q2 2023. 179 funds tracked by Wall St. Rank hold KURA as of Q3 2024.

  • MYDA Advisors reported no remaining Kura Oncology position as of Q3 2024 after selling out during the quarter.
  • MYDA Advisors sold 20,000 Kura Oncology shares in Q3 2024, an estimated $412K.
  • MYDA Advisors first reported a position in Kura Oncology in Q1 2022 and held it in 10 quarters.
  • MYDA Advisors's Kura Oncology position peaked at $846K in Q2 2023.
  • 179 funds tracked by Wall St. Rank held Kura Oncology as of Q3 2024.

Based on MYDA Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.